Health & Fitness
Health and Fitness
Health and Fitness
Mon, February 23, 2009 Editorial Article in the Clinical Chemistry Highlights Significant Progress in Optimization of the Non-Invasive Transrenal DNA
MONMOUTH JUNCTION, N.J.--([ BUSINESS WIRE ])--Xenomics, Inc. (Pink Sheets: XNOM), a developer of proprietary, non-invasive nucleic acid based molecular diagnostics, announces that the Clinical Chemistry published an editorial entitled "On Targeting Cell-Free DNA in Urine: A Protocol for Optimized DNA Analysis" on February 20th in its early online edition. The editorial provides an overview of the progress made in the area of testing for cell-free DNA in urine starting from pioneering work published by Xenomics' scientists in 2000, and discusses the latest paper "Optimization of Transrenal DNA Analysis: Detection of Fetal DNA in Maternal Urine" published by Xenomics in Clinical Chemistry on January 30th, 2009.
The authors of the editorial article, Drs. M. Bauer and B. Pertl from the Department of Obstetrics and Gynecology, Medical University Graz, Austria, note in conclusion: "The study reported by Shekhtman et al.provides important insights into the molecular characteristics of transrenal DNA. Based on their new technical approach of DNA isolation and amplification, urine has become for the first time a potent body fluid for noninvasive DNA analysis. The protocol for optimized transrenal DNA analysis might pave the road to interesting future studies in prenatal diagnosis and oncology and transplant medicine".
The launch of the first test based on these recent improvements of the transrenal DNA technology was announced by Xenomics on February 17, 2009. The test detects fetal gender by analysis of male-specific Y chromosome sequences in maternal urine collected as early as 7th week of pregnancy. The service is designed and offered solely for an expectant mother's information, does not provide any medical diagnoses or guidance and can be ordered at [ www.xenogentest.com ]. The implementation of the optimized transrenal nucleic acid technology in tests being developed in other areas is expected to both improve the accuracy of tests and accelerate their development.
About Xenomics
Xenomics is a molecular diagnostics company developing tests based on Transrenal nucleic acids (Tr-DNA and Tr-RNA including miRNA) and safe, simple urine collection techniques. The Company believes its proprietary technology has a broad range of detection / monitoring / screening applications, including prenatal conditions, infectious diseases, tissue transplantation, neurodegenerative disorders, various tumors, and can open significant new markets in the molecular diagnostics field. Currently, Xenomics is focusing on implementation of its urinary DNA-based test for high-risk Human Papilloma Virus (HPV) and development of other tests based on Tr-DNA and Tr-miRNA. Xenomics has a strong and broad IP portfolio of issued and pending patents covering different applications of the technology for molecular diagnostics.
Forward-Looking Statements
Statements about the Company's expectations, the significance of clinical study results, applications of its technology, markets, and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product development, government regulation, market acceptance, dependence on key personnel, obtaining financing and other factors discussed in the Company's periodic reports filed with the Securities and Exchange Commission.
More information is available on the Company's website, [ www.xenomics.com ].
